These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 23200793)

  • 1. Considerations on the EU definition of a nanomaterial: science to support policy making.
    Bleeker EA; de Jong WH; Geertsma RE; Groenewold M; Heugens EH; Koers-Jacquemijns M; van de Meent D; Popma JR; Rietveld AG; Wijnhoven SW; Cassee FR; Oomen AG
    Regul Toxicol Pharmacol; 2013 Feb; 65(1):119-25. PubMed ID: 23200793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The carcinogenic potential of nanomaterials, their release from products and options for regulating them.
    Becker H; Herzberg F; Schulte A; Kolossa-Gehring M
    Int J Hyg Environ Health; 2011 Jun; 214(3):231-8. PubMed ID: 21168363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measuring nanoparticles size distribution in food and consumer products: a review.
    Calzolai L; Gilliland D; Rossi F
    Food Addit Contam Part A Chem Anal Control Expo Risk Assess; 2012 Aug; 29(8):1183-93. PubMed ID: 22725833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards a more effective and efficient governance and regulation of nanomaterials.
    Teunenbroek TV; Baker J; Dijkzeul A
    Part Fibre Toxicol; 2017 Dec; 14(1):54. PubMed ID: 29258600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. European nanomaterial legislation in the past 20 years - Closing the final gaps.
    Nielsen MB; Skjolding L; Baun A; Hansen SF
    NanoImpact; 2023 Oct; 32():100487. PubMed ID: 37821007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Risks associated with nanotechnology based on European Union legislation].
    Hydzik P
    Przegl Lek; 2012; 69(8):490-1. PubMed ID: 23243915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The hierarchy of environmental health and safety practices in the U.S. nanotechnology workplace.
    Engeman CD; Baumgartner L; Carr BM; Fish AM; Meyerhofer JD; Satterfield TA; Holden PA; Harthorn BH
    J Occup Environ Hyg; 2013; 10(9):487-95. PubMed ID: 23927041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparative analysis of modern approaches to risk estimation from artificially created nanoparticles and nanomaterials].
    Kazak AA; Stepanov EG; Gmoshinskiĭ IV; Khotimchenko SA
    Vopr Pitan; 2012; 81(4):11-7. PubMed ID: 23156045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toward the development of decision supporting tools that can be used for safe production and use of nanomaterials.
    Som C; Nowack B; Krug HF; Wick P
    Acc Chem Res; 2013 Mar; 46(3):863-72. PubMed ID: 23110540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of nanomaterials in food and consumer products: bridging the gap from legislation to enforcement.
    Stamm H; Gibson N; Anklam E
    Food Addit Contam Part A Chem Anal Control Expo Risk Assess; 2012 Aug; 29(8):1175-82. PubMed ID: 22725966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Technology: Nanomaterials need flexible regulation.
    Wickson F
    Nature; 2011 Aug; 476(7360):283. PubMed ID: 21850092
    [No Abstract]   [Full Text] [Related]  

  • 12. Nanotechnology safety concerns revisited.
    Stern ST; McNeil SE
    Toxicol Sci; 2008 Jan; 101(1):4-21. PubMed ID: 17602205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A critical appraisal of existing concepts for the grouping of nanomaterials.
    Arts JH; Hadi M; Keene AM; Kreiling R; Lyon D; Maier M; Michel K; Petry T; Sauer UG; Warheit D; Wiench K; Landsiedel R
    Regul Toxicol Pharmacol; 2014 Nov; 70(2):492-506. PubMed ID: 25108058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Considerations when submitting nanotherapeutics to FDA/CDER for regulatory review.
    Tyner K; Sadrieh N
    Methods Mol Biol; 2011; 697():17-31. PubMed ID: 21116951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Issues in consumer exposure modeling: towards harmonization on a global scale.
    Kephalopoulos S; Bruinen de Bruin Y; Arvanitis A; Hakkinen P; Jantunen M
    J Expo Sci Environ Epidemiol; 2007 Dec; 17 Suppl 1():S90-100. PubMed ID: 17668010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanotechnology: the next big thing, or much ado about nothing?
    Maynard AD
    Ann Occup Hyg; 2007 Jan; 51(1):1-12. PubMed ID: 17041243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dealing with nanosafety around the globe-Regulation vs. innovation.
    Wacker MG; Proykova A; Santos GML
    Int J Pharm; 2016 Jul; 509(1-2):95-106. PubMed ID: 27184102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limits and prospects of the "incremental approach" and the European legislation on the management of risks related to nanomaterials.
    Franco A; Hansen SF; Olsen SI; Butti L
    Regul Toxicol Pharmacol; 2007 Jul; 48(2):171-83. PubMed ID: 17509740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health impact assessment: assessing opportunities and barriers to intersectoral health improvement in an expanded European Union.
    Lock K; McKee M
    J Epidemiol Community Health; 2005 May; 59(5):356-60. PubMed ID: 15831682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
    Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
    Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.